Lipoprotein(a): An Underappreciated Inherited Risk Factor for Atherosclerosis, Aortic Stenosis, and Abdominal Aortic Aneurysm

Elevated plasma concentration of lipoprotein(a) is a highly prevalent, independent, and causal risk factor for the development of numerous cardiovascular diseases. This review summarizes the key clinical evidence for elevated lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease, aortic stenosis, and abdominal aortic aneurysm. These data are specifically linked to ongoing developments in understanding the pathophysiological mechanisms of lipoprotein(a) in these contexts. Highly potent lipoprotein(a)-lowering therapies are being studied in cardiovascular outcomes trials for their ability to prevent major adverse coronary events and aortic stenosis progression, potentially ushering in a new era of clinical management of lipoprotein(a).

Authors

Institutions

Publication Details

Journal
Annual Review of Medicine
Published
2025-11-14
DOI
https://doi.org/10.1146/annurev-med-050124-025051
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lipoprotein(a): An Underappreciated Inherited Risk Factor for Atherosclerosis, Aortic Stenosis, and Abdominal Aortic Aneurysm

Michael B. Boffa, Marlys L. Koschinsky, Dinesh Kalra
Annual Review of Medicine
Lipoproteins and Cardiovascular Health
article

Lipoprotein(a): An Underappreciated Inherited Risk Factor for Atherosclerosis, Aortic Stenosis, and Abdominal Aortic Aneurysm

Michael B. Boffa, Marlys L. Koschinsky, Dinesh Kalra
article en

Abstract

Elevated plasma concentration of lipoprotein(a) is a highly prevalent, independent, and causal risk factor for the development of numerous cardiovascular diseases. This review summarizes the key clinical evidence for elevated lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease, aortic stenosis, and abdominal aortic aneurysm. These data are specifically linked to ongoing developments in understanding the pathophysiological mechanisms of lipoprotein(a) in these contexts. Highly potent lipoprotein(a)-lowering therapies are being studied in cardiovascular outcomes trials for their ability to prevent major adverse coronary events and aortic stenosis progression, potentially ushering in a new era of clinical management of lipoprotein(a).

Annual Review of MedicineVol. 77(1)
Western University (CA), University of Louisville (US), Robarts Clinical Trials (CA)
Openalex Percentile: Top 47%
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.